Curated News
By: NewsRamp Editorial Staff
May 13, 2026

Oncotelic Doses First Patient in Phase 1b Trial of Sapu003 for Solid Tumors

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Oncotelic's Sapu003 IV everolimus could overcome oral drug limitations, offering a competitive edge in advanced cancer treatment.
  • The Phase 1b trial evaluates Sapu003's safety, tolerability, pharmacokinetics, and anti-tumor activity in multiple advanced solid tumors.
  • This trial aims to improve cancer treatment by addressing oral everolimus issues, potentially enhancing patient quality of life.
  • Sapu003 uses Deciparticle technology to deliver everolimus intravenously weekly, a novel approach to mTOR inhibition.

Impact - Why it Matters

This news matters because Sapu003's novel IV formulation of everolimus could overcome the limitations of oral delivery, such as variable absorption and toxicity, potentially offering a more effective and tolerable treatment for patients with advanced mTOR-sensitive solid tumors, including breast cancer. If successful, it may set a new standard for everolimus administration and improve outcomes for cancer patients.

Summary

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company, alongside Sapu Nano, has announced that the first patient has been dosed in the Phase 1b clinical trial evaluating Sapu003, an investigational intravenous Deciparticle(TM) formulation of everolimus. This open-label, dose-escalation study targets patients with advanced mTOR-sensitive solid tumors, including HR-positive/HER2-negative breast cancer and multiple additional tumor types. The trial aims to assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. Sapu003 is developed as a weekly IV formulation intended to address limitations associated with oral everolimus delivery, such as variable absorption and dose-limiting toxicity. This advancement could potentially transform treatment options for patients with these challenging cancers.

Oncotelic Therapeutics, Inc. is dedicated to developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company's CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued patents, contributing to a robust pipeline. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform for research, biomarker discovery, and regulatory processes. Beyond internal programs, Oncotelic licenses and co-develops drug candidates through strategic partnerships, including a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline. For the latest news and updates on OTLC, visit the company's newsroom at https://ibn.fm/OTLC.

BioMedWire ("BMW") is a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It is part of the Dynamic Brand Portfolio @ IBN, which delivers a vast network of wire solutions, editorial syndication to 5,000+ outlets, enhanced press release distribution, social media reach, and tailored corporate communications solutions. BMW aims to cut through information overload to provide unparalleled recognition and brand awareness for its clients.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic Doses First Patient in Phase 1b Trial of Sapu003 for Solid Tumors

blockchain registration record for this content.